JP5118492B2 - 血栓の形成の防止および／または安定化の防止 - Google Patents

血栓の形成の防止および／または安定化の防止 Download PDF

Info

Publication number
JP5118492B2
JP5118492B2 JP2007547323A JP2007547323A JP5118492B2 JP 5118492 B2 JP5118492 B2 JP 5118492B2 JP 2007547323 A JP2007547323 A JP 2007547323A JP 2007547323 A JP2007547323 A JP 2007547323A JP 5118492 B2 JP5118492 B2 JP 5118492B2
Authority
JP
Japan
Prior art keywords
fxii
mice
thrombus
injury
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007547323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525342A5 (enExample
JP2008525342A (ja
Inventor
ベルンハルト・ニーズヴァント
トーマス・レネ
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2008525342A publication Critical patent/JP2008525342A/ja
Publication of JP2008525342A5 publication Critical patent/JP2008525342A5/ja
Application granted granted Critical
Publication of JP5118492B2 publication Critical patent/JP5118492B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007547323A 2004-12-23 2005-12-20 血栓の形成の防止および／または安定化の防止 Expired - Lifetime JP5118492B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030593 2004-12-23
EP04030593.0 2004-12-23
PCT/EP2005/013714 WO2006066878A1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization

Publications (3)

Publication Number Publication Date
JP2008525342A JP2008525342A (ja) 2008-07-17
JP2008525342A5 JP2008525342A5 (enExample) 2009-02-19
JP5118492B2 true JP5118492B2 (ja) 2013-01-16

Family

ID=34927953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547323A Expired - Lifetime JP5118492B2 (ja) 2004-12-23 2005-12-20 血栓の形成の防止および／または安定化の防止

Country Status (14)

Country Link
US (3) US8119137B2 (enExample)
EP (2) EP2272565A3 (enExample)
JP (1) JP5118492B2 (enExample)
KR (1) KR101277097B1 (enExample)
CN (1) CN101102819A (enExample)
AU (1) AU2005318464B2 (enExample)
BR (1) BRPI0519349A8 (enExample)
CA (1) CA2591786C (enExample)
DK (1) DK1830924T3 (enExample)
ES (1) ES2407965T3 (enExample)
MX (1) MX2007006997A (enExample)
PL (1) PL1830924T3 (enExample)
RU (1) RU2514878C2 (enExample)
WO (1) WO2006066878A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1542710T3 (da) 2002-08-28 2012-10-15 Dyax Corp Fremgangsmåde til konservering af organer og væv
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DK2526962T3 (da) * 2007-02-12 2019-10-07 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2215256A1 (en) * 2007-10-22 2010-08-11 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2103311A1 (en) 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
EP2145900A1 (en) 2008-07-15 2010-01-20 CSL Behring GmbH Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2269597A1 (en) 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
HRP20220107T1 (hr) 2010-01-06 2022-04-15 Takeda Pharmaceutical Company Limited Proteini koji vežu kalikrein plazme
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
US9150864B2 (en) * 2010-11-08 2015-10-06 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN103415301A (zh) * 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP6253578B2 (ja) * 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
WO2013028069A1 (en) * 2011-08-23 2013-02-28 Synapse B.V. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
KR20160026905A (ko) * 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
AU2015276089B2 (en) 2014-06-18 2021-03-18 Csl Behring Gmbh Therapy using a Factor XII inhibitor in a neurotraumatic disorder
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
CA2982413A1 (en) * 2015-04-28 2016-11-03 Ecole Polytechnique Federale De Lausanne (Epfl) Novel inhibitors of the enzyme activated factor xii (fxiia)
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3440107A4 (en) 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
AU2018382222B2 (en) 2017-12-15 2025-09-04 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
CN112437682B (zh) 2018-06-19 2024-11-05 里珍纳龙药品有限公司 抗因子XII/XIIa抗体和其用途
US12134657B2 (en) 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
BR112022000113A2 (pt) 2019-07-08 2022-03-15 Activesite Pharmaceuticals Inc Processos para preparação de inibidores de calicreí-na de plasma
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
CN116670280A (zh) 2020-12-18 2023-08-29 Ionis 制药公司 用于调节因子xii的化合物和方法
AU2024291721A1 (en) 2023-07-19 2026-01-22 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1994020535A1 (en) 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
GB9800817D0 (en) 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
ATE274600T1 (de) * 1998-06-08 2004-09-15 Univ Vermont Verfahren zur bestimmung der blutgerinnung in plasma
JP2002525298A (ja) * 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤の投与による炎症疾患の処置法
ATE468136T1 (de) * 2001-01-11 2010-06-15 D Collen Res Foundation Vzw Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2528254T3 (es) * 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
WO2004004640A2 (en) 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
DK1542710T3 (da) * 2002-08-28 2012-10-15 Dyax Corp Fremgangsmåde til konservering af organer og væv
US20040229778A1 (en) 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
DK1626736T3 (da) 2003-05-16 2020-09-28 Pharming Intellectual Property B V C1-inhibitor med kort halveringstid til midlertidig behandling
US8152750B2 (en) 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
GB0411145D0 (en) 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
GB0418877D0 (en) 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20060104944A1 (en) 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
SI1669074T1 (sl) 2004-12-01 2010-10-29 Par Pharmaceuticals Inc Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja

Also Published As

Publication number Publication date
ES2407965T3 (es) 2013-06-17
US8715672B2 (en) 2014-05-06
EP2272565A2 (en) 2011-01-12
US20080254039A1 (en) 2008-10-16
DK1830924T3 (da) 2013-05-21
EP1830924A1 (en) 2007-09-12
BRPI0519349A8 (pt) 2017-09-12
WO2006066878A1 (en) 2006-06-29
KR101277097B1 (ko) 2013-06-20
RU2007123797A (ru) 2009-01-10
AU2005318464A1 (en) 2006-06-29
PL1830924T3 (pl) 2013-08-30
KR20070092303A (ko) 2007-09-12
US20120148688A1 (en) 2012-06-14
CA2591786C (en) 2013-07-16
BRPI0519349A2 (pt) 2009-01-20
EP2272565A3 (en) 2012-03-28
US20130164301A1 (en) 2013-06-27
CN101102819A (zh) 2008-01-09
CA2591786A1 (en) 2006-06-29
JP2008525342A (ja) 2008-07-17
AU2005318464B2 (en) 2012-02-23
RU2514878C2 (ru) 2014-05-10
EP1830924B1 (en) 2013-02-27
MX2007006997A (es) 2007-10-10
US8119137B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
JP5118492B2 (ja) 血栓の形成の防止および／または安定化の防止
Renné et al. Defective thrombus formation in mice lacking coagulation factor XII
US11124787B2 (en) ADAMTS13-containing compositions having thrombolytic activity
Westaby Aprotinin in perspective
Esmon et al. An update on clinical and basic aspects of the protein C anticoagulant pathway
US9243044B2 (en) Anticoagulant polypeptide and applications thereof
KR20020062698A (ko) 혈전성 질환에 대한 보호용 약제
Renné et al. Factor XI deficiency in animal models
AU2014301041A1 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
EP2895184A1 (en) Modulation of podoplanin mediated platelet activation
US20130071396A1 (en) Method of inhibiting coagulation activation with human anti-factor v antibodies and use thereof
US20080219998A1 (en) Anti-Thrombotic Agents
Hirsh et al. C. Thrombogenesis
HK1116438A (en) Prevention of thrombus formation and/or stabilization
EP1915175A2 (en) Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents
Esmon Coagulation and Innate Immunity
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema
Westaby Aprotinin Fifteen Years Later
Hagedorn Novel mechanisms underlying arterial thrombus formation: in vivo studies in (genetically modified) mice
Patient Transfusion Medicine and Coagulation Disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121019

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5118492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250